KCM
RAPT

Kingdon Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Kingdon Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,500
Closed -$3.67M – 102
2021
Q4 		$3.67M Buy
+12,500
New +$3.34M 0.42% 56
2021
Q3 		– Sell
-25,000
Closed -$6.36M – 79
2021
Q2 		$6.36M Buy
25,000
+6,250
+33% +$1.17M 0.74% 43
2021
Q1 		$3.33M Buy
+18,750
New +$3.09M 0.34% 53

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Kingdon Capital Management's RAPT Position: Q1 2025 in Review

Kingdon Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 71,875 shares — an estimated $909K sold.

Kingdon Capital Management first reported a position in RAPT in Q4 2020 and held it in 17 quarters. The position peaked at $42.2M in Q4 2021. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Kingdon Capital Management reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Kingdon Capital Management sold 71,875 RAPT Therapeutics shares in Q1 2025, an estimated $909K.
  • Kingdon Capital Management first reported a position in RAPT Therapeutics in Q4 2020 and held it in 17 quarters.
  • Kingdon Capital Management's RAPT Therapeutics position peaked at $42.2M in Q4 2021.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Kingdon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.